Brigatinib treatment for primary lung lesions in non-small-cell lung cancer based on ALK gene rearrangement detected in resected brain metastases: A case report and literature review

Background: Lung cancer is the main cause of brain metastasis, primary lesions in patients with brain metastases from lung cancer are most often treated with surgery, and adjuvant chemoradiotherapy and other therapeutic methods are used to control disease progression based on the characteristics of the primary lesions. Materials and methods: Here, we report a case of a patient with NSCLC who received brigatinib treatment for the primary lung lesions after the resection of brain metastases based on the ALK gene rearrangement detected in the resected brain metastases by highthroughput sequencing. Results: The result of ten months follow-up showed satisfactory curative effect. The primary lung lesions disappeared and no sign of recurrence in the brain and lung. Conclusion: This method provides a new option for the treatment of primary lung lesions in patients with brain metastases from lung cancer.